The material, called imidazolium oligomers, is made of a synthetic chemical compound linked in chains, which enables it to destroy bacteria by penetrating cell membranes, unlike antibiotics, which leave bacterial cell structures intact.
“Our unique material can kill bacteria rapidly and inhibit the development of antibiotic-resistant bacteria,” Yugen Zhang, PhD, lead researcher on the paper, said in a statement. “Computational chemistry studies supported our experimental findings that the chain-like compound works by attacking the cell membrane. This material is also safe for use because it carries a positive charge that targets the more negatively charged bacteria, without destroying red blood cells.”
The researchers also tested their material against Staphylococcus aureus, Candida albicans, and other common strains of antibiotic-resistant bugs, all of which were killed as effectively as E. coli.
More articles on infection control:
Pittsburgh hospitals focus on stewardship after ‘super’ superbug found in Penn.
Common antimicrobial agent quickly disrupts gut microbiomes, study finds
NQF, CDC release practical antibiotic stewardship playbook: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
